呼吸器ウイルスワクチン市場レポート：動向、予測、競合分析 (2031年まで)

世界の呼吸器ウイルスワクチン市場の将来は、医院、病院、診療所、薬局・店舗市場での機会が有望視されています。世界の呼吸器ウイルスワクチン市場は、2025年から2031年までのCAGRが7.4%で、2031年までに推定145億米ドルに達すると予想されます。この市場の主な促進要因は、呼吸器ウイルス感染率の上昇、ワクチンの利点に対する意識の高まり、ワクチン開発の迅速化と普及のための政府支出の増加です。

• Lucintelの予測によると、ワクチンの種類別では、強力で持続的な免疫反応を刺激する不活化/キルドワクチンが予測期間中に最も高い成長を遂げる見込みです。
• 最終用途カテゴリーでは、病院が予測期間中に最も高い成長を遂げると予想されます。
• 地域別では、北米は強力な医療インフラと政府資金により、予測期間中に最も高い成長が見込まれます。

呼吸器ウイルスワクチン市場の戦略的成長機会

呼吸器ウイルスワクチン市場は、ワクチン技術の進歩、需要の増加、公衆衛生の優先順位の変化などを背景に、重要な用途においていくつかの戦略的成長機会を明確に提供しています。

• 混合ワクチン：多数の呼吸器ウイルスを予防する混合ワクチンの開発は、大きな成長機会となります。このアプローチにより予防接種スケジュールを合理化することで、ワクチンの全体的な摂取率が向上します。
• mRNAワクチン技術：呼吸器ウイルスワクチンにmRNA技術を活用することは、成長の可能性を秘めています。その柔軟性と迅速な開発能力により、新たな呼吸器系の脅威に対処する上で価値があります。
• 万能ワクチン：万能型呼吸器ウイルスワクチンの研究に投資することで、市場を前進させることができます。これらのワクチンは幅広い防御を提供し、複数のワクチンの必要性を減らすことができます。
• 高度な送達方法：点鼻薬やマイクロニードルパッチなど、予防接種を送達するための新たなアプローチを探求することは、成長分野です。これらにより、ワクチンの投与方法や患者への受け入れられ方が改善されます。
• 市場アクセスの拡大：十分なサービスを受けていない市場や新興市場におけるワクチンへのアクセスの改善は、拡大の大きなチャンスです。流通網の強化や現地生産により、ワクチンの入手可能性や適用範囲に関するギャップを埋めることができます。

これらの要因により、呼吸器ウイルスワクチン市場は技術革新に拍車がかかり、適用範囲が拡大されるとともに、ワクチンへのアクセスが容易になります。これらは、呼吸器ウイルスの発生に効果的に対応しながら、世界の健康実績を向上させる上で特に不可欠です。

呼吸器ウイルスワクチン市場促進要因・課題

技術的進歩、経済的決定要因、規制上の問題など、様々な要因が呼吸器ウイルスワクチン市場を促進または阻害します。これらの要素を理解することは市場開拓に不可欠です。

呼吸器ウイルスワクチン市場の促進要因には以下のようなものがあります：

• 技術の進歩：技術の進歩：mRNAワクチンや混合ワクチンなど、ワクチン技術の革新が市場の成長を後押しします。これらの進歩により、新型ウイルスに対するワクチンの有効性、安全性、柔軟性が向上します。
• ワクチン需要の増加：呼吸器系ウイルスの急増は、公衆衛生キャンペーンの継続と相まって、ワクチン需要を刺激しています。その結果、ワクチン開発と生産への投資が増加しています。
• 政府の支援：政府の支援政策と潜在的な流通チャネルに関する調査への資金援助が主要な促進要因です。政府のイニシアチブは、ワクチンの入手しやすさを促進し、公衆衛生の目標を支援します。
• ワクチンへのアクセスの拡大：流通システムの改善とワクチン製造能力の向上により、十分なサービスを受けていない地域へのアクセスが拡大しています。これにより、地域間の格差が解消され、より多くの人々が予防接種プログラムの対象となります。
• 研究開発（R&D）：継続的な研究開発活動は、ワクチン技術や供給方法の革新に不可欠です。このような研究開発なくして、新しいワクチンの開発や既存ワクチンの改良はあり得ません。

呼吸器ウイルスワクチン市場における課題は以下の通り：

• 規制上のハードル：ワクチン承認に必要な複雑な規制要件をクリアすることは困難です。国際規格への適合はプロセスを複雑にし、市場参入に影響します。
• 高コスト：ワクチンの開発・製造に関連する高コストにより、手頃な価格が妨げられる可能性があります。この問題は、ワクチンの入手が制限されている低資源国で特に関連します。
• ワクチンへのためらい：ワクチン接種へのためらいをなくし、誤った情報に対処することは、ワクチン接種率を高めるのに役立ちます。ワクチン受容の障壁をなくすためには、公衆教育キャンペーンが不可欠です。

これらの促進要因・課題は、呼吸器ウイルスワクチン市場におけるイノベーション、アクセス、公衆衛生への取り組みに大きな影響を与えます。これらの要因に対処することで、ワクチン開発、流通、そして人々の健康状態全体を改善することが可能です。

目次

第1章 エグゼクティブサマリー

第2章 世界の呼吸器ウイルスワクチン市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 市場動向と予測分析 (2019年～2031年)

• マクロ経済動向 (2019～2024年) と予測 (2025～2031年)
• 世界の呼吸器ウイルスワクチン市場の動向 (2019～2024年) と予測 (2025～2031年)
• 世界の呼吸器ウイルスワクチン市場：種類別
  • 不活性化/殺菌
  • 弱毒生
  • 組み換え
• 世界の呼吸器ウイルスワクチン市場：投与経路別
  • 筋肉内
  • 鼻腔内
  • 皮下
• 世界の呼吸器ウイルスワクチン市場：適応症別
  • インフルエンザ
  • 麻疹
  • おたふく風邪と風疹
  • コロナウイルス
• 世界の呼吸器ウイルスワクチン市場：最終用途別
  • 開業医
  • 病院
  • クリニック
  • 薬局/店舗
  • その他

第4章 地域別の市場動向と予測分析 (2019年～2031年)

• 世界の呼吸器ウイルスワクチン市場：地域別
• 北米の呼吸器ウイルスワクチン市場
• 欧州の呼吸器ウイルスワクチン市場
• アジア太平洋の呼吸器ウイルスワクチン市場
• その他地域の呼吸器ウイルスワクチン市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 世界の呼吸器ウイルスワクチン市場の成長機会：種類別
  • 世界の呼吸器ウイルスワクチン市場の成長機会：投与経路別
  • 世界の呼吸器ウイルスワクチン市場の成長機会：適応症別
  • 世界の呼吸器ウイルスワクチン市場の成長機会：最終用途別
  • 世界の呼吸器ウイルスワクチン市場の成長機会：地域別
• 世界の呼吸器ウイルスワクチン市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界の呼吸器ウイルスワクチン市場の生産能力拡大
  • 世界の呼吸器ウイルスワクチン市場における企業合併・買収 (M&A)、合弁事業
  • 認証とライセンシング

第7章 主要企業のプロファイル

• Sanofi
• AstraZeneca
• Merck
• GlaxoSmithKline
• Serum Institute of India
• Moderna
• Bavarian Nordic

The future of the global respiratory virus vaccine market looks promising with opportunities in the physician office, hospital, clinic, and pharmacy/store markets. The global respiratory virus vaccine market is expected to reach an estimated $14.5 billion by 2031 with a CAGR of 7.4% from 2025 to 2031. The major drivers for this market are the rising rate of respiratory viral infections, growing awareness of the benefits of vaccines, and increasing government spending to fast-track the development of vaccines and ensure widespread access.

• Lucintel forecasts that, within the type category, inactivated/killed is expected to witness the highest growth over the forecast period due to their ability to stimulate a powerful and enduring immune response.
• Within the end-use category, the hospital is expected to witness the highest growth over the forecast period.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to its strong healthcare infrastructure and government funding.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Respiratory Virus Vaccine Market

The market for vaccines against respiratory viruses is transforming due to several key trends driven by technological advancements and changes in public health demands. These developments have defined the future of preventing respiratory viruses.

• Combination Vaccines: More attention is now being directed toward the development of vaccines that can protect against multiple respiratory infections, such as flu, COVID-19, and RSV. The purpose of combination vaccines is to simplify vaccination schedules and increase compliance.
• mRNA Technology: mRNA technology is not only meant for COVID-19 vaccinations. Researchers are also investigating its potential application in developing vaccines targeting different respiratory viral diseases, thus offering swift development and adaptability to new strains.
• Universal Respiratory Virus Vaccines: Attempts are being made to design universal vaccines that can offer broad protection against many kinds of respiratory viruses. By reducing the need for multiple shots, these universal vaccines can improve overall health outcomes in communities.
• Enhanced Delivery Methods: Research is being conducted on utilizing nasal sprays and microneedle patches, among other delivery methods, aiming to improve ease of administration as well as patient acceptance. These methods aim to increase vaccination rates and accessibility.
• Global Collaboration: Faster development and distribution of vaccines against respiratory viruses have been facilitated through increased international collaboration. Global partnerships seek to share research findings, resources, and distribution networks that better position everyone involved in addressing respiratory infections globally.

These trends focus on improving vaccine technology, broadening protection coverage, and enhancing delivery mechanisms, thereby altering the landscape of the respiratory virus vaccine market. They are necessary for tackling emerging threats from viruses causing respiratory illnesses while also positively influencing overall community well-being.

Recent Developments in the Respiratory Virus Vaccine Market

Advancements in the respiratory virus vaccine market are characterized by significant milestones involving the adoption of new technologies and approaches to enhance the effectiveness and accessibility of vaccines. Recent advancements have focused on increasing protection and managing emerging viral threats.

• Combination Vaccine Development: Ongoing efforts are aimed at developing combination vaccines that address influenza, COVID-19, and other respiratory viruses. The main aim of these vaccines is to simplify vaccination schedules and enhance overall immunity.
• Universal Vaccine Research: Progress is being made in research aimed at producing universal vaccines that can protect against various respiratory viruses. Such vaccines could lessen the need for multiple shots and offer more complete protection.
• Improved Vaccine Delivery: Innovations are being made regarding how vaccines will be administered, such as nasal sprays and microneedle patches. These methods seek to improve vaccine compliance among patients while ensuring better delivery procedures.
• Increased Production Capacity: Scaling up production capacity for vaccines, particularly in emerging markets, is critical in meeting growing demand and achieving equal distribution of vaccines.

These developments significantly influence the respiratory virus vaccine market through technological improvements, better delivery options, and increased manufacturing capacities, which are essential for improving global responses to viral threats to public health.

Strategic Growth Opportunities for Respiratory Virus Vaccine Market

The respiratory virus vaccine market distinctly offers several strategic growth opportunities across important applications, driven by advancements in vaccine technology, increasing demand, and shifting public health priorities.

• Combination Vaccines: Developing combination vaccines that protect against numerous respiratory viruses creates a significant growth opportunity. Streamlining immunization schedules through this approach improves overall vaccine uptake.
• mRNA Vaccine Technology: Utilizing mRNA technology for respiratory virus vaccines has growth potential. It is valuable for addressing emerging respiratory threats due to its flexibility and quick development capabilities.
• Universal Vaccines: Investing in universal respiratory virus vaccine research can propel the market forward. These vaccines could provide broad protection and reduce the need for multiple vaccines.
• Advanced Delivery Methods: Exploring new approaches to delivering vaccinations, including nasal sprays and microneedle patches, represents areas of growth. These will improve how the vaccine is administered and how it is accepted by patients.
• Expanded Market Access: Improving access to vaccines in underserved and emerging markets is a major opportunity for expansion. Enhanced distribution networks and local production can bridge gaps related to vaccine availability and coverage.

These factors are shaping the respiratory virus vaccine market by spurring innovation and extending coverage while making vaccines easily accessible to users. They are particularly essential in improving global health performance while effectively responding to respiratory virus incidences.

Respiratory Virus Vaccine Market Driver and Challenges

Various factors drive or hinder the respiratory virus vaccine market, including technological advancements, economic determinants, and regulatory issues. Understanding these components is critical for market development.

The factors responsible for driving the respiratory virus vaccine market include:

• Technological Advancements: Innovation in vaccine technology, such as mRNA and combination vaccines, boosts market growth. These advancements enhance the efficacy, safety, and flexibility of vaccines against new strains of viruses.
• Increased Demand for Vaccines: The surging prevalence of respiratory viruses, coupled with ongoing public health campaigns, stimulates demand for vaccines. This has resulted in increased investments in vaccine development and production.
• Government Support: Supportive government policies and financing for research on potential distribution channels are key drivers. Government initiatives promote the accessibility of vaccines and support public health goals.
• Expanded Vaccine Access: Better distribution systems and increased vaccine manufacturing capacity have expanded access to underserved areas. This helps to bridge gaps between communities while ensuring that more people are covered by immunization programs.
• Research and Development (R&D): Continuous R&D activities are crucial for innovations in vaccine technology and delivery methods. Without this kind of research, no new vaccines can be developed or improvements made to existing ones.

Challenges in the respiratory virus vaccine market include:

• Regulatory Hurdles: Navigating complex regulatory requirements for vaccine approval may be challenging. Conforming to international standards complicates the process and affects market entry.
• High Costs: Affordability could be hampered by high costs associated with developing and producing vaccines. This problem is particularly relevant in low-resource countries where vaccine availability is limited.
• Vaccine Hesitancy: Combatting hesitancy toward vaccination and addressing misinformation can help raise vaccination rates. Public education campaigns are essential to eliminate barriers to vaccine acceptance.

These drivers and challenges significantly impact innovation, access, and public health efforts in the respiratory virus vaccine market. By addressing these factors, it is possible to improve vaccine development, distribution, and the overall health status of the population.

List of Respiratory Virus Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies respiratory virus vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the respiratory virus vaccine companies profiled in this report include-

• Sanofi
• AstraZeneca
• Merck
• GlaxoSmithKline
• Serum Institute of India
• Moderna
• Bavarian Nordic

Respiratory Virus Vaccine by Segment

The study includes a forecast for the global respiratory virus vaccine market by type, route of administration, indication, end use, and region.

Respiratory Virus Vaccine Market by Type [Analysis by Value from 2019 to 2031]:

• Inactivated/Killed
• Live-Attenuated
• Recombinant

Respiratory Virus Vaccine Market by Route of Administration [Analysis by Value from 2019 to 2031]:

• Intramuscular
• Intranasal
• Subcutaneous

Respiratory Virus Vaccine Market by Indication [Analysis by Value from 2019 to 2031]:

• Influenza
• Measles
• Mumps & Rubella
• Coronavirus

Respiratory Virus Vaccine Market by End Use [Analysis by Value from 2019 to 2031]:

• Physician Offices
• Hospitals
• Clinics
• Pharmacies/Stores
• Others

Respiratory Virus Vaccine Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Respiratory Virus Vaccine Market

The market for respiratory virus vaccines is experiencing significant advancements driven by new pathogens, technologies, and changing public health needs. Improvements in the United States, China, Germany, India, and Japan indicate worldwide efforts toward better vaccine efficacy and availability against respiratory viral threats.

• U.S.: Updated vaccines against various respiratory viruses, including novel variants of influenza and RSV, have recently been approved in the U.S. The focus is on developing combined vaccines that work against different pathogens simultaneously to make immunization schedules more efficient.
• China: To curb the increasing number of respiratory virus infections, China's respiratory virus vaccine portfolio is advancing with innovative options for COVID-19 and influenza. Broader immunity coverage through a variety of strains is also a focus, while accessibility in urban cities and rural areas has been optimized.
• Germany: Germany is investing in next-generation respiratory virus vaccines, which include those with improved efficacy against seasonal flu and emerging respiratory viruses. Additionally, investment is directed toward mRNA vaccine technology for wider applications.
• India: The country is beginning to increase production capacity for respiratory virus vaccines, addressing the rising demand for COVID-19 and seasonal flu vaccines. Public health campaigns are being intensified to improve vaccination coverage in underserved regions.
• Japan: Advanced vaccinations offering prolonged protection and minimal side effects are currently being developed in Japan. Equally important are studies pursuing non-injectable administration modes for increased acceptance and convenience for the population.

Features of the Global Respiratory Virus Vaccine Market

Market Size Estimates: Respiratory virus vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Respiratory virus vaccine market size by various segments, such as by type, route of administration, indication, end use, and region in terms of ($B).

Regional Analysis: Respiratory virus vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, route of administrations, indications, end uses, and regions for the respiratory virus vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the respiratory virus vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the respiratory virus vaccine market by type (inactivated/killed, live-attenuated, and recombinant), route of administration (intramuscular, intranasal, and subcutaneous), indication (influenza, measles, mumps & rubella, and coronavirus), end use (physician offices, hospitals, clinics, pharmacies/stores, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Respiratory Virus Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Respiratory Virus Vaccine Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Respiratory Virus Vaccine Market by Type
  • 3.3.1: Inactivated/Killed
  • 3.3.2: Live-Attenuated
  • 3.3.3: Recombinant
• 3.4: Global Respiratory Virus Vaccine Market by Route of Administration
  • 3.4.1: Intramuscular
  • 3.4.2: Intranasal
  • 3.4.3: Subcutaneous
• 3.5: Global Respiratory Virus Vaccine Market by Indication
  • 3.5.1: Influenza
  • 3.5.2: Measles
  • 3.5.3: Mumps & Rubella
  • 3.5.4: Coronavirus
• 3.6: Global Respiratory Virus Vaccine Market by End Use
  • 3.6.1: Physician Offices
  • 3.6.2: Hospitals
  • 3.6.3: Clinics
  • 3.6.4: Pharmacies/Stores
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Respiratory Virus Vaccine Market by Region
• 4.2: North American Respiratory Virus Vaccine Market
  • 4.2.1: North American Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
  • 4.2.2: North American Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others
• 4.3: European Respiratory Virus Vaccine Market
  • 4.3.1: European Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
  • 4.3.2: European Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others
• 4.4: APAC Respiratory Virus Vaccine Market
  • 4.4.1: APAC Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
  • 4.4.2: APAC Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others
• 4.5: ROW Respiratory Virus Vaccine Market
  • 4.5.1: ROW Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
  • 4.5.2: ROW Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Type
  • 6.1.2: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Route of Administration
  • 6.1.3: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Indication
  • 6.1.4: Growth Opportunities for the Global Respiratory Virus Vaccine Market by End Use
  • 6.1.5: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Region
• 6.2: Emerging Trends in the Global Respiratory Virus Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Respiratory Virus Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Respiratory Virus Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Sanofi
• 7.2: AstraZeneca
• 7.3: Merck
• 7.4: GlaxoSmithKline
• 7.5: Serum Institute of India
• 7.6: Moderna
• 7.7: Bavarian Nordic